

Natalie E Cusano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8637487/publications.pdf>

Version: 2024-02-01

35
papers

2,260
citations

304743

22
h-index

395702

33
g-index

36
all docs

36
docs citations

36
times ranked

1675
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary hyperparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2024, 38, 101247.	4.7	13
2	Evaluation and Management of Elevated Parathyroid Hormone Levels in Normocalcemic Patients. Medical Clinics of North America, 2021, 105, 1135-1150.	2.5	3
3	Smoking Is Associated with Sex-Specific Effects on Bone Microstructure in Older Men and Women. Journal of Clinical Densitometry, 2020, 24, 341-350.	1.2	1
4	Changes in Skeletal Microstructure Through Four Continuous Years of rhPTH(1-84) Therapy in Hypoparathyroidism. Journal of Bone and Mineral Research, 2020, 35, 1274-1281.	2.8	14
5	Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2748-2756.	3.6	44
6	Skeletal Microstructure and Estimated Bone Strength Improve Following Parathyroidectomy in Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 196-205.	3.6	45
7	Trabecular Bone Score in Obese and Nonobese Subjects With Primary Hyperparathyroidism Before and After Parathyroidectomy. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1512-1521.	3.6	27
8	Hyperparathyroidism. Lancet, The, 2018, 391, 168-178.	13.7	371
9	Primary hyperparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 593-607.	4.7	81
10	Management of normocalcemic primary hyperparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 837-845.	4.7	55
11	Signs and Symptoms of Hypoparathyroidism. Endocrinology and Metabolism Clinics of North America, 2018, 47, 759-770.	3.2	32
12	The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry. Journal of Bone and Mineral Research, 2018, 33, 1931-1939.	2.8	24
13	Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 2018, 33, 2132-2139.	2.8	19
14	Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism. Endocrine, 2017, 55, 591-598.	2.3	47
15	Effects of Parathyroid Hormone Administration on Bone Strength in Hypoparathyroidism. Journal of Bone and Mineral Research, 2016, 31, 1082-1088.	2.8	18
16	Noninvasive Assessment of Skeletal Microstructure and Estimated Bone Strength in Hypoparathyroidism. Journal of Bone and Mineral Research, 2016, 31, 308-316.	2.8	67
17	Management of Hypoparathyroidism: Present and Future. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2313-2324.	3.6	151
18	Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2742-2750.	3.6	101

#	ARTICLE	IF	CITATIONS
19	PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. Expert Review of Endocrinology and Metabolism, 2015, 10, 5-13.	2.4	22
20	Parathyroid hormone therapy for hypoparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 47-55.	4.7	29
21	Bone disease in primary hyperparathyroidism. Arquivos Brasileiros De Endocrinologia E Metabologia, 2014, 58, 553-561.	1.3	104
22	PTH(1-84) Is Associated With Improved Quality of Life in Hypoparathyroidism Through 5 Years of Therapy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3694-3699.	3.6	104
23	Parathyroid Hormone in the Evaluation of Hypercalcemia. JAMA - Journal of the American Medical Association, 2014, 312, 2680.	7.4	11
24	Parathyroid Hormone 1-84 Alters Circulating Vascular Endothelial Growth Factor Levels in Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2025-E2028.	3.6	5
25	The Effect of PTH(1-84) on Quality of Life in Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2356-2361.	3.6	169
26	Comparative effectiveness of combination osteoanabolic and antiresorptive therapy for osteoporosis: an update. Journal of Comparative Effectiveness Research, 2013, 2, 511-513.	1.4	0
27	Normocalcemic Primary Hyperparathyroidism. Journal of Clinical Densitometry, 2013, 16, 33-39.	1.2	145
28	Therapy of Hypoparathyroidism with PTH(1-84): A Prospective Four-Year Investigation of Efficacy and Safety. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 137-144.	3.6	148
29	Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. Journal of Bone and Mineral Research, 2013, 28, 1029-1040.	2.8	174
30	Normocalcemic Hyperparathyroidism and Hypoparathyroidism in Two Community-Based Nonreferral Populations. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2734-2741.	3.6	116
31	Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai. Bone Research, 2013, 1, 162-169.	11.4	45
32	Primary Hyperparathyroidism after Laser Therapy to the Larynx. Endocrine Practice, 2013, 19, 888-890.	2.1	2
33	Combination Anabolic and Antiresorptive Therapy for Osteoporosis. Endocrinology and Metabolism Clinics of North America, 2012, 41, 643-654.	3.2	22
34	Mini-review: new therapeutic options in hypoparathyroidism. Endocrine, 2012, 41, 410-414.	2.3	32
35	Therapy of Osteoporosis in Men with Teriparatide. Journal of Osteoporosis, 2011, 2011, 1-7.	0.5	18